Alzheimer's Disease: Potential Benefit of Isoflavones
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 55 - Any |
| Updated: | 10/14/2017 |
| Start Date: | January 2005 |
| End Date: | December 2009 |
The purpose of this pilot study is to evaluate the potential effects of soy isoflavone
supplements on cognitive function for men and women with Alzheimer's Disease (AD).
Preliminary studies evaluating the effects of soy supplements on memory in cognitively
healthy older adults have yielded promising results that are now being evaluated in patients
with AD. It is hypothesized that isoflavone supplements will ameliorate cognitive declines
for older adults diagnosed with Alzheimer's disease, when compared to subjects on placebo.
supplements on cognitive function for men and women with Alzheimer's Disease (AD).
Preliminary studies evaluating the effects of soy supplements on memory in cognitively
healthy older adults have yielded promising results that are now being evaluated in patients
with AD. It is hypothesized that isoflavone supplements will ameliorate cognitive declines
for older adults diagnosed with Alzheimer's disease, when compared to subjects on placebo.
Inclusion Criteria:
- Diagnosis of probable AD
- Has reliable and available caregiver to assist with medication and appointments
- On a stable dose of cholinesterase inhibitor, or if unable to tolerate medication,
patient has no plans to re-initiate cholinergic therapies while in the study
Exclusion Criteria:
- Current or recent use (<6 months) of menopausal HRT
- Current or recent use (<4 months) or oral antibiotic therapy
- Typical dietary intake of soy isoflavones >5 mg/day
- History or significant gastro-intestinal or colon disease, or colon/intestinal
resection
- Irritable bowel syndrome
- History of breast cancer, or abnormal mammogram within 12 months
- History of chronic obstructive pulmonary disease, diabetes mellitus, liver disease or
unstable ischemic heart disease
- Significant neurological disease other than AD that might affect cognitive function,
such as stroke, Parkinson's disease, multiple sclerosis, or serious traumatic brain
injury
We found this trial at
1
site
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Click here to add this to my saved trials
